How to buy Sorrento Therapeutics stock | 9.3

Sorrento Therapeutics, Inc is a biotechnology business based in the US. Sorrento Therapeutics shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therapeutics employs 310 staff and has a trailing 12-month revenue of around USD$35.5 million.

How to buy shares in Sorrento Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sorrento Therapeutics. Find the stock by name or ticker symbol: SRNE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sorrento Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$9.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sorrento Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sorrento Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Sorrento Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Sorrento Therapeutics's share price has had significant positive movement.

Its last market close was USD$9.3, which is 72.69% up on its pre-crash value of USD$2.54 and 500.00% up on the lowest point reached during the March crash when the shares fell as low as USD$1.55.

If you had bought USD$1,000 worth of Sorrento Therapeutics shares at the start of February 2020, those shares would have been worth USD$554.05 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,513.51.

Sorrento Therapeutics share price

Use our graph to track the performance of SRNE stocks over time.

Sorrento Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$9.3
52-week range	USD$1.45 - USD$15.04
50-day moving average	USD$9.2506
200-day moving average	USD$6.9694
Wall St. target price	USD$25.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.404

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Sorrento Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sorrento Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sorrento Therapeutics price performance over time

Historical closes compared with the close of $9.3 from 2020-10-16

1 week (2020-10-23)	15.10%
1 month (2020-10-01)	-13.00%
3 months (2020-07-30)	8.77%
6 months (2020-04-30)	309.69%

1 year (2019-10-30)	515.89%
2 years (2018-10-30)	197.12%
3 years (2017-10-30)	257.69%
5 years (2015-10-30)	7.64%

Sorrento Therapeutics financials

Revenue TTM	USD$35.5 million
Gross profit TTM	USD$-87,684,000
Return on assets TTM	-20.42%
Return on equity TTM	-443.24%
Profit margin	0%
Book value	$0.612
Market capitalisation	USD$2.2 billion

TTM: trailing 12 months

Shorting Sorrento Therapeutics shares

There are currently 75.7 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 0.8% up from 75.1 million last month.

There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.

Sorrento Therapeutics's "short interest ratio" (SIR)

Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 32.4 million). Sorrento Therapeutics's SIR currently stands at 2.34. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 2340 shares are currently held short.

However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.29% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 290 shares are currently held short) or 0.2947% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 295 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sorrento Therapeutics.

Find out more about how you can short Sorrento Therapeutics stock.

Sorrento Therapeutics share dividends

We're not expecting Sorrento Therapeutics to pay a dividend over the next 12 months.

Have Sorrento Therapeutics's shares ever split?

Sorrento Therapeutics's shares were split on a 1:25 basis on 1 August 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.

Sorrento Therapeutics share price volatility

Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as $1.45 up to $15.04. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.6089. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sorrento Therapeutics overview

Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.

Frequently asked questions

• What percentage of Sorrento Therapeutics is owned by insiders or institutions?

  Currently 34.213% of Sorrento Therapeutics shares are held by insiders and 17.858% by institutions.

• How many people work for Sorrento Therapeutics?

  Latest data suggests 310 work at Sorrento Therapeutics.

• When does the fiscal year end for Sorrento Therapeutics?

  Sorrento Therapeutics's fiscal year ends in December.

• Where is Sorrento Therapeutics based?

  Sorrento Therapeutics's address is: 4955 Directors Place, San Diego, CA, United States, 92121

• What is Sorrento Therapeutics's ISIN number?

  Sorrento Therapeutics's international securities identification number is: US74838K4058

• What is Sorrento Therapeutics's CUSIP number?

  Sorrento Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74838K108